The last couple of days dragged down the performance a bit but still managed to get a 4.3% return in June. June was a good month for growth stocks which definitely helped the portfolio. Was busy due to college exams this month so not that much activity in the portfolio.
June was a special month for myself on FinTwit as I started to post my first stock-specific threads and content and I will keep posting deep dives on here. Next thread coming Saturday. 😎Thanks for the great feedback so far and welcome to all the new followers - means a lot.😇
Only new position is $PGNY check out the work of my brother @camiadeluca if interested:
McKinsey published a 200-pages report on the impact of biotech in May earlier this year and I want to summarize the most important points for you today.
Feel free to reach out and I will send you the whole report.
1) Introduction
Lately, there has been a sharp drop in the cost of sequencing DNA and emerging technologies to edit genes and reprogram cells have helped to increase innovation. Scientists suggest that 60% of physical inputs in the global economy could be produced biologically.
Of this 60%, 1/3 are biological materials and 2/3 aren’t but could be produced or substituted using biology. 45% of the current global disease burden could be addressed using science that is conceivable today. Combining all the use cases that are available today
I will start this thread by saying this is my first stock deep dive so any feedback and sharing is highly appreciated.
Let me introduce this company and tell you why it's a top 3 position for me.
CELLINK ($CLNK.B, @CELLINK3D) specialises in bioconvergence.
1) What is bioconvergence?
Bioconvergence combines the fields of software/engineering and biology. It isn't limited to specific combinations like bioinformatics or bioprinting but can be applied to an end-to-end approach and brings out the best of science and technology.
2) CELLINK's role in bioconvergence
CELLINK specialises in bioprinting and bioprocessing and is one of the world-leading bioconvergence companies. Rather than focussing on only bioprinters, CELLINK provides a combination of printer and bioink which is protected by many patents.